Edwards Lifesciences officer files to sell $238K in stock

Edwards Lifesciences Corp (EW) is the issuer for which officer Annette Bruls filed a notice under Rule 144 to permit the sale of common stock.

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) is the issuer for which officer Annette Bruls filed a notice under Rule 144 to permit the sale of common stock. The filing covers up to 2,644 shares of common stock to be sold through Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $237,907.00 and total shares outstanding of 576,400,000. The securities to be sold include shares acquired via restricted stock lapses from equity compensation awards.

Key Figures

Shares to be sold under Rule 144: 2,644 shares Aggregate market value: $237,907.00 Shares outstanding: 576,400,000 shares +2 more

5 metrics

Shares to be sold under Rule 144 2,644 shares Common stock covered by the notice for potential sale

Aggregate market value $237,907.00 Market value of the 2,644 common shares covered by the notice

Shares outstanding 576,400,000 shares Edwards Lifesciences Corp common shares outstanding referenced in the filing

Restricted Stock Lapse shares (07/11/2025) 1,911 shares Equity compensation common stock from restricted stock lapse on 07/11/2025

Restricted Stock Lapse shares (05/08/2026) 733 shares Equity compensation common stock from restricted stock lapse on 05/08/2026

Key Terms

Rule 144, Restricted Stock Lapse, Equity Compensation, common stock

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse financial

"Common | 05/08/2026 | Restricted Stock Lapse | EDWARDS LIFESCIENCES"

Equity Compensation financial

"733 | 05/08/2026 | Equity Compensation Common | 07/11/2025"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

common stock financial

"144: Securities Information Common | Charles Schwab & Co., Inc."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What does the Form 144 filing for EW by Annette Bruls disclose?

It discloses that officer Annette Bruls has filed to potentially sell 2,644 shares of Edwards Lifesciences Corp (EW) common stock under Rule 144, with an aggregate market value of $237,907.00, through Charles Schwab & Co., Inc. on the NYSE.

How many EW shares are covered by this Form 144 notice?

The notice covers up to 2,644 shares of Edwards Lifesciences Corp common stock for potential sale under Rule 144.

What is the aggregate market value of EW shares in this Form 144?

The aggregate market value of the Edwards Lifesciences Corp shares covered by this Form 144 is $237,907.00.

How many Edwards Lifesciences (EW) shares are outstanding as referenced in the filing?

The filing references 576,400,000 Edwards Lifesciences Corp common shares outstanding.

What is the approximate sale date for the EW shares in this Form 144?

The approximate sale date referenced for the potential sale of Edwards Lifesciences Corp shares is 08/28/2026.

How were some of the EW shares in this Form 144 acquired?

The shares include equity compensation acquired via Restricted Stock Lapse events, including 733 shares on 05/08/2026 and 1,911 shares on 07/11/2025 from Edwards Lifesciences Corporation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:19 PM Accepted by SEC EDGAR 08/28/2026 - 04:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002032351
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Bruls Annette
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	2644	237907.00	576400000	08/28/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/08/2026	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			733	05/08/2026	Equity Compensation
Common	07/11/2025	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			1911	07/11/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Annette Bruls
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)